Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 8, Number 8—August 2002

Research

Antecedent Treatment with Different Antibiotic Agents as a Risk Factor for Vancomycin-Resistant Enterococcus

Yehuda Carmeli*†Comments to Author , George M. Eliopoulos*†, and Matthew H. Samore*†
Author affiliations: *Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; †Harvard Medical School, Boston, Massachusetts, USA;

Main Article

Table 3

The effect of antibiotic treatment as risk factor for vancomycin-resistant enterococci

Cases
(%) Control (%) Unadjusted effect Adjusted for explanatory modela Adjusted for model
and other antibioticsa
Antibiotic agent
(233)
(647)
OR
p
value
OR
(95% CI)
p
value
OR
(95% CI)
p
value
Penicillins 67 (29) 134 (21) 1.5 0.04 .99 (.63 to 1.6) 0.97 1.0 (.64 to 1.7) 0.86
β-lactam-inhibitor combination 49 (21) 98 (15) 1.5 0.07 .94 (.6 to 1.5) 0.78
Cephalosporins 104 (45) 248 (38) 1.2 0.28 1.5 (1.0 to 2.4) 0.048
Third generation 69 (30) 97 (15) 2.6 <0.001 2.8 (1.7 to 4.5) <0.001 2.8 (1.7 to 4.8) <0.001
Vancomycin (p.o.) 4 (1.7) 7 (1.1) 1.2 083 1.0 (.25 to 4.2) 0.96
Vancomycin (i.v.) 67 (29) 121 (19) 1.7 0.016 1.4 (.89 to 2.3) 0.19 .99 (.57 to 1.7) 0.98
Metronidazole (p.o.) 13 (5.6) 23 (3.6) 1.5 0.29 1.0 (.42 to 2.5) 0.97
Metronidazole (i.v.) 47 (20) 57 (9) 2.5 <0.001 2.3 (1.3 to 3.9) 0.003 2.1 (1.2 to 3.7) 0.008
Clindamycin 20 (8.6) 51 (7.9) 1 0.9 1.5 (.76 to 2.8) 0.26 1.1 (.55 to 2.3) 0.76
Quinoloneb 48 (21) 68 (11) 2 0.005 1.6 (.94 to 2.6) 0.086 1.5 (.85 to 2.6)b 0.17b
Imipenem 19 (8.2) 27 (4.2) 1.7 0.12 1.3 (.61 to 2.9) 0.47 1.2 (.52 to 2.8) 0.66

aAdjusted for the explanatory model detailed in Table 2.
b When included as a continuous variable (number of days of treatment with quinolone) OR=1.03, p=0.05.
OR, odds ratio; p.o., orally; i.v., intravenously.

Main Article

TOP